BNT
BioNTech (BNTX) Q1 2026 Earnings
BNTX·Reported May 5, 2026·Before market open
BioNTech reported Q1 2026 revenue of $136.4M (-31.9% YoY), missed analyst consensus of $207.4M by $71.0M. Diluted EPS came in at $-2.28 (-25.3% YoY), beat the $-2.52 consensus by $0.24.
Revenue
$136.4Mmissed by $71.0M
Consensus: $207.4MDiluted EPS
$-2.28beat by $0.24
Consensus: $-2.52
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2026 Earnings FAQ
Common questions about BioNTech's Q1 2026 earnings report.
BioNTech (BNTX) reported Q1 2026 earnings on May 5, 2026 before market open.
BioNTech reported revenue of $136.4M and diluted EPS of $-2.28 for Q1 2026.
Revenue missed the consensus estimate of $207.4M by $71.0M. EPS beat the consensus estimate of $-2.52 by $0.24.
Compared to the same quarter a year prior, revenue declined 31.9% from $200.4M a year earlier and diluted EPS declined 25.3% from $-1.82.